These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10642222)

  • 21. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
    Banwell B; Tremlett H
    Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
    [No Abstract]   [Full Text] [Related]  

  • 22. A new approach for MS.
    Morrow T
    Manag Care; 2005 Jan; 14(1):85-7. PubMed ID: 15742758
    [No Abstract]   [Full Text] [Related]  

  • 23. Multiple sclerosis and Natalizumab.
    Fiore D
    Am J Ther; 2007; 14(6):555-60. PubMed ID: 18090880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.
    Gonsette RE; Dubois B
    J Neurol Sci; 2004 Aug; 223(1):81-6. PubMed ID: 15261566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Drug therapy in multiple sclerosis].
    Le Page E; Edan G
    Rev Prat; 2006 Jun; 56(12):1336-46. PubMed ID: 16948222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical industry agenda setting in mental health policies.
    Gosden R; Beder S
    Ethical Hum Sci Serv; 2001; 3(3):147-59. PubMed ID: 15278977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continence in MS.
    Sneddon D
    Prof Nurse; 2001 Apr; 16(7):1241-4. PubMed ID: 12026785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New era for MS treatment. Severe setback when it comes to enthusiasm--highly effective agent caused serious adverse effects].
    Olsson T
    Lakartidningen; 2006 Apr 26-May 2; 103(17):1282-3. PubMed ID: 16708855
    [No Abstract]   [Full Text] [Related]  

  • 29. Health care lobbying in the United States.
    Landers SH; Sehgal AR
    Am J Med; 2004 Apr; 116(7):474-7. PubMed ID: 15047037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy in multiple sclerosis.
    Fernández O
    J Neurol Sci; 2007 Aug; 259(1-2):95-103. PubMed ID: 17507031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitoxantrone-related acute leukemia in two MS patients.
    Pielen A; Goffette S; Van Pesch V; Gille M; Sindic CJ
    Acta Neurol Belg; 2008 Sep; 108(3):99-102. PubMed ID: 19115673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug companies' lobbying of ministers has little effect on NICE.
    Jack A
    BMJ; 2006 Oct; 333(7571):719. PubMed ID: 17023447
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.
    Neuhaus O; Hartung HP
    Expert Rev Neurother; 2007 May; 7(5):547-56. PubMed ID: 17492904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MS treatment: postmarketing studies.
    Montalban X
    J Neurol Sci; 2007 Aug; 259(1-2):42-5. PubMed ID: 17383679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
    Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
    J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis in childhood: understanding and caring for children with an "adult" disease.
    Boyd JR; MacMillan LJ
    Axone; 2000 Dec; 22(2):15-21. PubMed ID: 11901486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH
    Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis.
    Bolton C
    Inflammopharmacology; 2007 Oct; 15(5):183-7. PubMed ID: 17943249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
    Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
    Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The new partnership in multiple sclerosis: relations with industry.
    Reingold SC
    Mult Scler; 1995 Nov; 1(3):141-2. PubMed ID: 9345443
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.